Developing fit-for-purpose self-report instruments for assessing consumer responses to tobacco and nicotine products: the ABOUTâ„¢ Toolbox initiative


Authored by  C Chrea, C Acquadro*, E. F. Afolalu, E Spies, T Salzberger, L Abetz-Webb*, S Cano, B Arnould*, N Mainy, R Weitkunat

Published in F1000Research    
* This author is not affiliated with PMI.
Abstract


Background:
Determining the public health impact of tobacco harm reduction strategies requires the assessment of consumer perception and behavior associated with tobacco and nicotine products (TNPs) with different exposure and risk profiles. In this context, rigorous methods to develop and validate psychometrically sound self-report instruments to measure consumers’ responses to TNPs are needed.

Methods: Consistent with best practice guidelines, including the U.S. Food and Drug Administration’s “Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims,”scientifically designed, fit-for-purpose, reliable, and valid instruments are now being applied to tobacco regulatory research.

Results: This brief report presents the ABOUT™ Toolbox (Assessment of Behavioral OUtcomes related to Tobacco and nicotine products) initiative. This communication: (1) describes the methodological steps followed for the development and validation of the measurement instruments included in the ABOUT™ Toolbox, (2) presents a summary of the high-priority tobacco-related domains that are currently covered in the ABOUT™ Toolbox (i.e., risk perception, dependence, product experience, health and functioning, and use history), and (3) details how the measurement instruments are made accessible to the scientific community.

Conclusions: By making the ABOUT™ Toolbox available to the tobacco research and public health community, we envision a rapidly expanding knowledge base, with the goals of (1) supporting consumer perception and behavior research to allow comparisons across a wide spectrum of TNPs, (2) enabling public health and regulatory communities to make better-informed decisions for future regulation of TNPs, and (3) enhancing surveillance activities associated with the impact of TNPs on population health.